Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Phase 2

Completed

Conditions: Hematologic Diseases
Myeloma
Lymphoma
Leukemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2008-12-02

Last Posted Date: 2016-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00800839

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Phase 1

Terminated

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Myelodysplastic/Myeloproliferative Neoplasms
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

First Posted Date: 2008-12-01

Last Posted Date: 2015-06-08

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 6

Registration Number: NCT00800150

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Phase 2

Completed

Conditions: Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia in Remission
Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome (MDS)

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Drug: Treosulfan
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2008-11-24

Last Posted Date: 2023-02-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 130

Registration Number: NCT00796068

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Acute Leukaemia
Myelodysplasia
Chronic Disease
Leukemia
Lymphoma

Interventions: Drug: Busulfan
Drug: Anti-Thymocyte Globulin
Drug: Fludarabine
Drug: Cyclosporine
Drug: Mycophenolate mofetil

First Posted Date: 2008-11-21

Last Posted Date: 2013-07-30

Lead Sponsor: University of Utah

Target Recruit Count: 47

Registration Number: NCT00795132

Locations: 🇺🇸
Primary Children's Medical Center, Salt Lake City, Utah, United States

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2008-11-20

Last Posted Date: 2018-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 66

Registration Number: NCT00794820

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Plasma Cell Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bortezomib
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Syngeneic Bone Marrow Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2008-11-19

Last Posted Date: 2020-01-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00793572

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma
Acute Myeloid Leukemia
Refractory Chronic Lymphocytic Leukemia
Aggressive Non-Hodgkin Lymphoma
Refractory Plasma Cell Myeloma
Recurrent Chronic Lymphocytic Leukemia
Refractory Hodgkin Lymphoma
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Indolent Adult Non-Hodgkin Lymphoma

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Biological: Natural Killer Cell Therapy
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2008-11-13

Last Posted Date: 2020-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 41

Registration Number: NCT00789776

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Haploidentical Stem Cell Transplantation in Neuroblastoma

Early Phase 1

Conditions: Neuroblastoma

Interventions: Drug: iodine I 131 metaiodobenzylguanidine
Drug: Fludarabine
Drug: Thiotepa
Procedure: T-cell depletion
Procedure: Haploidentical stem cell transplantation
Procedure: Donor Lymphocyte Infusion
Drug: Rituximab
Procedure: Co-transplantation of mesenchymal stem cells

First Posted Date: 2008-11-13

Last Posted Date: 2021-02-21

Lead Sponsor: Lund University Hospital

Target Recruit Count: 15

Registration Number: NCT00790413

Locations: 🇸🇪
Lund University Hospital, Department of Pediatric Oncology and Bone Marrow Transplantation, Lund, Sweden

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Phase 2

Completed

Conditions: Myeloproliferative Disorders
Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: anti-thymocyte globulin
Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methotrexate
Drug: tacrolimus
Procedure: nonmyeloablative allogeneic HSCT

First Posted Date: 2008-11-10

Last Posted Date: 2012-10-01

Lead Sponsor: Northside Hospital, Inc.

Target Recruit Count: 24

Registration Number: NCT00787761

Locations: 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Lymphoma
Leukemia
Myelodysplastic Syndromes

Interventions: Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2008-10-31

Last Posted Date: 2013-11-21

Lead Sponsor: Northside Hospital, Inc.

Target Recruit Count: 20

Registration Number: NCT00782379

Locations: 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy